Trial Looks to Double Down on Anti-HER2 in Breast Cancer

Currently enrolling, HER2CLIMB-04 combines two newly approved drugs, Both tucatinib (Tukysa) and trastuzumab deruxtecan (Enhertu) have been shown to be highly efficacious in the pivotal HER2CLIMB and DESTINY-Breast01 trials, respectively.

A new study presented at the recent American Society of Clinical Oncology (ASCO) virtual annual meeting aims to assess if the combination of the agents in patients with HER2-positive locally advanced/metastatic breast cancer can further improve the efficacy seen with either agent alone.

HER2CLIMB-4 was presented by Dr. [Ian E.] Krop here at ASCO 2021. And it’s a really exciting study because it combines two of our newest approved drugs in the HER2 space together into one trial. So obviously I’m talking about tucatinib and trastuzumab deruxtecan here.